ICPT
Closed
Intercept Pharmaceuticals Inc
19.
0 (0.00%)
Last Update: 14 Nov 2023 17:30:00
Yesterday: 19.
Day's Range: 19. - 19.
Send
sign up or login to leave a comment!
When Written:
13.53
Intercept Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat chronic liver diseases. The company was founded in 2002 and is headquartered in New York City.
Intercept's lead product, Ocaliva (obeticholic acid), is approved for the treatment of primary biliary cholangitis (PBC), a rare autoimmune liver disease. The company is also developing other drug candidates for the treatment of nonalcoholic steatohepatitis (NASH) and other liver diseases.
Intercept has partnerships with several pharmaceutical companies, including Sumitomo Dainippon Pharma, Takeda Pharmaceuticals, and Genfit SA. The company has a global presence, with operations in the United States, Europe, and Asia.
Intercept has faced challenges in recent years, including safety concerns related to Ocaliva and setbacks in clinical trials for its NASH drug candidate. However, the company remains committed to developing innovative therapies for liver diseases and improving patient outcomes.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Intercept's lead product, Ocaliva (obeticholic acid), is approved for the treatment of primary biliary cholangitis (PBC), a rare autoimmune liver disease. The company is also developing other drug candidates for the treatment of nonalcoholic steatohepatitis (NASH) and other liver diseases.
Intercept has partnerships with several pharmaceutical companies, including Sumitomo Dainippon Pharma, Takeda Pharmaceuticals, and Genfit SA. The company has a global presence, with operations in the United States, Europe, and Asia.
Intercept has faced challenges in recent years, including safety concerns related to Ocaliva and setbacks in clinical trials for its NASH drug candidate. However, the company remains committed to developing innovative therapies for liver diseases and improving patient outcomes.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








